Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline

Rafols, Ismael and Hopkins, Michael M and Hoekman, Jarno and Siepel, Josh and O'Hare, Alice and Perianes-Rodríguez, Antonio and Nightingale, Paul Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline. Technological Forecasting and Global Change, 2014, vol. 81, pp. 22-38. (In Press) [Journal article (Paginated)]

[img] Text
Rafols_2012_preprint.pdf - Accepted version

Download (4MB)

English abstract

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms (Big Pharma) during the period 1995–2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that Big Pharma are increasingly becoming ‘network integrators’ rather than the prime locus of drug discovery.

Item type: Journal article (Paginated)
Keywords: Pharmaceuticals; Bibliometrics; Outsourcing; Europe; Globalisation; Research network; Innovation; Collaboration
Subjects: A. Theoretical and general aspects of libraries and information. > AC. Relationship of LIS with other fields .
B. Information use and sociology of information
B. Information use and sociology of information > BB. Bibliometric methods
B. Information use and sociology of information > BC. Information in society.
Depositing user: Antonio Perianes-Rodríguez
Date deposited: 25 Nov 2014 12:40
Last modified: 25 Nov 2014 12:40
URI: http://hdl.handle.net/10760/24128

References

"SEEK" links will first look for possible matches inside E-LIS and query Google Scholar if no results are found.

Amir-Aslani, A., Mangematin, V., 2010. The future of drug discovery and development: Shifting emphasis towards personalized medicine. Technological Forecasting and Social Change 77, 203-217.

Angell, M., 2004. The truth about the drug companies. How they deceive us and what to do about it. Random House, New York.

Archibugi, D., Iammarino, S., 1999. The policy implications of the globalisation of innovation. Research Policy 28, 317-336.

Arrowsmith, J., 2012. A decade of change. Nat Rev Drug Discov 11, 17-18.

AstraZeneca, 2010. AstraZeneca Annual Report 2010. AstraZeneca, London.

Baum, A., 2010. Pharmaceuticals: Exit research and create value.

BIS, 2009. [ARCHIVED CONTENT] Policy: Innovation: R&D Scoreboard - BIS [WWW Document]. URL http://webarchive.nationalarchives.gov.uk/20101208170217/http://www.innovation.gov.uk/rd_scoreboard/?p=31

Bonaccorsi, A., 2008. Search regimes and the industrial dynamics of science. Minerva 46, 285-315.

Chesbrough, H., 2003. Open Innovation: The New Imperative for Creating and Profiting from Technology. Harvard University Press, Boston.

Cockburn, I.M., Henderson, R.M., 1998. Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery. The Journal of Industrial Economics 46, 157-182.

Collins, F.S., 2011. Reengineering Translational Science: The Time Is Right. Science Translational Medicine 3, 90cm17.

Crommelin, D., Stolk, P., Besancon, L., Shah, V., Midha, K., Leufkens, H., 2010. Pharmaceutical sciences in 2020. Nat Rev Drug Discov 9, 99-100.

D'Este, P., 2005. How do firms' knowledge bases affect intra-industry heterogeneity?: An analysis of the Spanish pharmaceutical industry. Research Policy 34, 33-45.

Dasgupta, P., David, P.A., 1994. Toward a new economics of science. Research Policy 23, 487-521.

David, P.A., 1998. Common agency contracting and the emergence of" open science" institutions. The American Economic Review 88, 15-21.

DiMasi, J.A., Faden, L.B., 2011. Competitiveness in follow-on drug R&D: a race or imitation? Nat Rev Drug Discov 10, 23-27.

Dosi, G., Llerena, P., Labini, M.S., 2006. The relationships between science, technologies and their industrial exploitation: An illustration through the myths and realities of the so-called "European Paradox." Research Policy 35, 1450-1464.

van Eck, N., Waltman, L., 2010. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84, 523-538.

Evolving R&D for emerging markets., 2010. Nat Rev Drug Discov 9, 417-420.

Friedman, Y., 2010. Location of pharmaceutical innovation: 2000-2009. Nat Rev Drug Discov 9, 835-836.

Garnier, J.-P., 2008. Rebuilding the R&D Engine in Big Pharma. Harvard Business Review 69-76.

Herper, M., 2011. A Decade In Drug Industry Layoffs [WWW Document]. URL http://www.forbes.com/sites/matthewherper/2011/04/13/a-decade-in-drug-industry-layoffs/

Hicks, D., 1995. Published Papers, Tacit Competencies and Corporate Management of the Public/Private Character of Knowledge. Industrial and Corporate Change 4, 401 -424.

Hicks, D., Katz, J.S., 1996. Where Is Science Going? Science, Technology, & Human Values 21, 379-406.

Hirschler, B., Kelland, K., 2010. Big Pharma, Small R&D. Reuters, London.

Hoekman, J., Frenken, K., de Zeeuw, D., Lambers-Heerspink, H.J., 2012. The geographical constitution of leadership in globalized clinical trials. mimeo.

Hopkins, M.M., Martin, P.A., Nightingale, P., Kraft, A., Mahdia, S., 2007. The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Research Policy 36.

Howells, J., Gagliardi, D., Malik, K., 2008. The growth and management of R&D outsourcing: evidence from UK pharmaceuticals. R&D Management 38, 205-219.

Hwang, J., Christensen, C.M., 2008. Disruptive Innovation In Health Care Delivery: A Framework For Business-Model Innovation. Health Affairs 27, 1329-1335.

Jensen, D.G., 2010. Little "r," Big "D" --Science Jobs [WWW Document]. URL http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2010_12_17/caredit.a1000122

Jong, S., Slavcheva, K., 2012. To share or not to?: Publishing strategies and R&D productivity in science-based industries. In preparation.

Kneller, R., 2010. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 9, 867-882.

LaMattina, J.L., 2011. The impact of mergers on pharmaceutical R&D. Nature Reviews Drug Discovery 10, 559-560.

Leydesdorff, L., Rotolo, D., Rafols, I., 2012. Bibliometric Perspectives on Medical Innovation using the Medical Subject Headings (MeSH) of PubMed. Journal of the American Society for Information Science and Technology In press.

Leydesdorff, L., Wagner, C., 2009. Is the United States losing ground in science? A global perspective on the world science system. Scientometrics 78, 23-36.

Mazzucato, M., 2011. The entrepreneurial state. Demos, London.

McBride, R., Hollmer, M., 2012. Top 10 pharma layoffs of 2011 [WWW Document]. URL http://www.fiercepharma.com/special-reports/top-10-pharma-layoffs-2011?utm_medium=nl&utm_source=internal

McKelvey, M., Orsenigo, L., Pammolli, F., 2004. Pharmaceutical analized through the lens of a sectoral innovation system, in: Malerba, F. (Ed), Sectoral Innovation Systems. Concepts, Issues and Analyses of Six Major Sectors in Europe. Cambridge University Press, Cambridge, pp. 73-120.

McMillan, G.S., Narin, F., Deeds, D.L., 2000. An analysis of the critical role of public science in innovation: the case of biotechnology. Research Policy 29, 1-8.

Merton, R., 1973. The normative structure of science, in: Press, U. o. C. (Ed), The Sociology of Science. Chicago and London, pp. 268-278 (tbc).

Montori, V.M., Guyatt, G.H., 2008. Progress in Evidence-Based Medicine. JAMA: The Journal of the American Medical Association 300, 1814 -1816.

Munos, B.H., 2009. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8, 959-968.

Munos, B.H., Chin, W.W., 2011. How to revive breakthrough innovation in the pharmaceutical industry. Science translational medicine 3, 89cm16.

Nightingale, P., 2000. Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Industrial and Corporate Change 9, 315 -359.

Nightingale, P., Martin, P., 2004. The myth of the biotech revolution. Trends in Biotechnology 22, 564-569.

Pammolli, F., Magazzini, L., Riccaboni, M., 2011. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10, 428-438.

Patel, P., Arundel, A., Hopkins, M.M., 2008. Sectoral Innovation Systems in Europe: Monitoring, Analysing Trends and Identifying Challenges in Biotechnology Europe Innova. SPRU, University of Sussex, Brighton, UK.

Patel, P., Pavitt, K., 1997. The technological competencies of the world's largest firms: Complex and path-dependent, but not much variety. Research Policy 26, 141-156.

Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., Schacht, A.L., 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9, 203-214.

Perianes-Rodríguez, A., Olmeda-Gómez, C., Moya-Anegón, F., 2010. Detecting, identifying and visualizing research groups in co-authorship networks. Scientometrics 82, 307-319.

Persson, O., Glänzel, W., Danell, R., 2004. Inflationary bibliometric values: The role of scientific collaboration and the need for relative indicators in evaluative studies. Scientometrics 60, 421-432.

Petryna, A., 2009. When experiments travel: clinical trials and the global search for human subjects. Princeton University Press, Princeton and Oxford.

Petsko, G.A., 2011. Herding CATS. Science Translational Medicine 3, 97cm24.

Pisano, G.P., 2006. Science Business: The Promise, the Reality, and the Future of Biotech. Harvard Business School Press, Boston, MA.

Polidoro, F., Theeke, M., 2011. Getting competition down to a science: the effects of technological competition on firms' scientific publication. Organization Science doi: 10.1287/orsc.1110.0684.

Porter, A.L., Rafols, I., 2009. Is Science Becoming more Interdisciplinary? Measuring and Mapping Six Research Fields over Time. Scientometrics 81, 719-745.

Powell, W.W., Koput, K.W., Smith-Doerr, L., 1996. Interoganizational collaboration and the locus of innovation: Networks of learning in biotechnology. Administrative Science Quaterly 41, 116-145.

Rafols, I., Porter, A.L., Leydesdorff, L., 2010. Science Overlay Maps: A New Tool for Research Policy and Library Management. Journal of the American Society for Information Science and Technology 61, 871-1887.

Ratner, M., 2012. Big pharma upheavals cast shadow across biotech sector. Nat Biotech 30, 119-120.

Sanofi-Aventis, 2010. Sanofi-Aventis Annual Report 2010. Sanofi-Aventis Groupe, France.

Sismondo, S., 2007. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine 4, e286.

Sismondo, S., 2009. Ghosts in the Machine. Social Studies of Science 39, 171 -198.

Smith, R., 2005. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med 2, e138.

Staton, T., 2011. Roche chief warns of perfect pharma storm [WWW Document]. Fiercepharma. URL http://www.fiercepharma.com/story/roche-chief-warns-perfect-pharma-storm/2011-12-07

Stephan, P., 1996. The economics of science. Journal of Economic Literature 34, 1199-1235.

Subramanian, R., Toney, J.H., Jayachandran, C., 2011. The evolution of research and development in the pharmaceutical industry: toward the open innovation model - can pharma reinvent itself? International Journal of Business Innovation and Research 5, 63-74.

The Economist, 2007. The rise and fall of corporate R&D: Out of the dusty labs. The Economist.

Thiers, F.A., Sinskey, A.J., Berndt, E.R., 2008. Trends in the globalization of clinical trials. Nat Rev Drug Discov 7, 13-14.

Tijssen, R.J.W., 2004. Is the commercialisation of scientific research affecting the production of public knowledge?: Global trends in the output of corporate research articles. Research Policy 33, 709-733.

Tijssen, R.J.W., 2009. Internationalisation of pharmaceutical R&D: how globalised are Europe's largest multinational companies? Technology Analysis & Strategic Management 21, 859-879.

Timmermans, S., Berg, M., 2003. The practice of medical technology. Sociology of Health & Illness 25, 97-114.

Ujjual, V., Patel, P., Krishnan, R.T., Keshavamurthy, S., Hsiao, R.-L., Zhao, F.Y., 2011. Management and Organisation of Knowledge Creation in Emerging Markets: a Perspective from Subsidiaries of EU MNEs. SPRU Electronic Working Papers 192.

Vallas, S.P., Kleinman, D.L., 2008. Contradiction, convergence and the knowledge economy: the confluence of academic and commercial biotechnology. Socio-Economic Review 6, 283 -311.

West, W., Nightingale, P., 2009. Organizing for innovation: towards successful translational research. Trends in Biotechnology 27, 558-561.

Wuchty, S., Jones, B.F., Uzzi, B., 2007. The Increasing Dominance of Teams in Production of Knowledge. Science 316, 1036 -1039.

von Zedtwitz, M., Gassmann, O., 2002. Market versus technology drive in R&D internationalization: four different patterns of managing research and development. Research Policy 31, 569-588.


Downloads

Downloads per month over past year

Actions (login required)

View Item View Item